S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
S&P 500   3,925.43
DOW   31,961.86
QQQ   324.13
Log in
NASDAQ:CTMX

CytomX Therapeutics Stock Forecast, Price & News

$8.04
+0.03 (+0.37 %)
(As of 02/24/2021 12:00 AM ET)
Add
Compare
Today's Range
$7.80
Now: $8.04
$8.20
50-Day Range
$6.60
MA: $7.85
$9.00
52-Week Range
$3.60
Now: $8.04
$15.44
Volume514,797 shs
Average Volume1.10 million shs
Market Capitalization$371.64 million
P/E RatioN/A
Dividend YieldN/A
Beta0.74
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 immuno-oncology target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel drug target; BMS-986249, a CTLA-4 Probody therapeutic drug for the treatment of metastatic melanoma; CX-2029, a PDC targeting CD71 for solid tumors; and BMS-986288, an anti-CTLA-4 Probody drug for solid tumors. The company has strategic collaborations with AbbVie Ireland Unlimited Company, Amgen, Inc., Bristol-Myers Squibb Company, ImmunoGen, Inc., Pfizer Inc., and Astellas Pharma Inc. to develop Probody therapeutics. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.
CytomX Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CTMX
CUSIPN/A
Phone650-515-3185
Employees158
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$57.49 million
Book Value$1.12 per share

Profitability

Net Income$-102,240,000.00

Miscellaneous

Market Cap$371.64 million
Next Earnings DateN/A
OptionableOptionable

MarketRank

Overall MarketRank

1.56 out of 5 stars

Medical Sector

364th out of 1,958 stocks

Pharmaceutical Preparations Industry

190th out of 772 stocks

Analyst Opinion: 3.3Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$8.04
+0.03 (+0.37 %)
(As of 02/24/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CTMX News and Ratings via Email

Sign-up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











CytomX Therapeutics (NASDAQ:CTMX) Frequently Asked Questions

Is CytomX Therapeutics a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CytomX Therapeutics in the last twelve months. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CytomX Therapeutics stock.
View analyst ratings for CytomX Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than CytomX Therapeutics?

Wall Street analysts have given CytomX Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but CytomX Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting CytomX Therapeutics?

CytomX Therapeutics saw a increase in short interest in the month of January. As of January 29th, there was short interest totaling 3,640,000 shares, an increase of 20.9% from the January 14th total of 3,010,000 shares. Based on an average daily volume of 783,800 shares, the days-to-cover ratio is presently 4.6 days.
View CytomX Therapeutics' Short Interest
.

How were CytomX Therapeutics' earnings last quarter?

CytomX Therapeutics, Inc. (NASDAQ:CTMX) announced its quarterly earnings data on Thursday, November, 5th. The biotechnology company reported ($0.32) earnings per share for the quarter, topping analysts' consensus estimates of ($0.36) by $0.04. The biotechnology company earned $17.79 million during the quarter, compared to analyst estimates of $17.45 million. CytomX Therapeutics had a negative net margin of 58.13% and a negative trailing twelve-month return on equity of 94.20%.
View CytomX Therapeutics' earnings history
.

How has CytomX Therapeutics' stock been impacted by Coronavirus (COVID-19)?

CytomX Therapeutics' stock was trading at $5.87 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CTMX shares have increased by 37.0% and is now trading at $8.04.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for CTMX?

8 brokers have issued twelve-month price objectives for CytomX Therapeutics' stock. Their forecasts range from $8.50 to $16.00. On average, they anticipate CytomX Therapeutics' share price to reach $12.21 in the next twelve months. This suggests a possible upside of 51.9% from the stock's current price.
View analysts' price targets for CytomX Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are CytomX Therapeutics' key executives?

CytomX Therapeutics' management team includes the following people:
  • Dr. Sean A. McCarthy, Chairman, CEO & Pres (Age 54, Pay $907.75k)
  • Mr. Frederick W. Gluck, Co-Founder & Independent Director (Age 86, Pay $49.38k)
  • Mr. Lloyd A. Rowland Jr., J.D., Sr. VP, Gen. Counsel, Chief Compliance Officer & Sec. (Age 64, Pay $574.06k)
  • Dr. Amy C. Peterson M.D., Exec. VP & Chief Devel. Officer (Age 54, Pay $2.17M)
  • Mr. Carlos Campoy, Sr. VP & CFO (Age 56)
  • Dr. Chau Cheng M.B.A., Ph.D., VP of Investor Relations & Corp. Communications
  • Dr. Sridhar Viswanathan Ph.D., Sr. VP of Process Sciences & Manufacturing Operations
  • Ms. Danielle Olander, Sr. VP, Talent & Systems Devel.
  • Ms. Alison Joly, Sr. VP of Program & Alliance Management
  • Ms. Leslie Robbins, Sr. VP of Intellectual Property

What is Sean A McCarthy's approval rating as CytomX Therapeutics' CEO?

11 employees have rated CytomX Therapeutics CEO Sean A McCarthy on Glassdoor.com. Sean A McCarthy has an approval rating of 65% among CytomX Therapeutics' employees.

Who are some of CytomX Therapeutics' key competitors?

What other stocks do shareholders of CytomX Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CytomX Therapeutics investors own include Gilead Sciences (GILD), Exelixis (EXEL), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Corbus Pharmaceuticals (CRBP), Pfizer (PFE), SCYNEXIS (SCYX), Bausch Health Companies (BHC), Bristol-Myers Squibb (BMY) and Dynavax Technologies (DVAX).

What is CytomX Therapeutics' stock symbol?

CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."

Who are CytomX Therapeutics' major shareholders?

CytomX Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.23%), Victory Capital Management Inc. (5.01%), Renaissance Technologies LLC (4.47%), Nuveen Asset Management LLC (1.32%), Northern Trust Corp (1.13%) and Federated Hermes Inc. (0.78%). Company insiders that own CytomX Therapeutics stock include Lloyd A Rowland and Sean A Mccarthy.
View institutional ownership trends for CytomX Therapeutics
.

Which institutional investors are selling CytomX Therapeutics stock?

CTMX stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Russell Investments Group Ltd., Renaissance Technologies LLC, Panagora Asset Management Inc., Victory Capital Management Inc., Trexquant Investment LP, Congress Park Capital LLC, and Tudor Investment Corp Et Al.
View insider buying and selling activity for CytomX Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying CytomX Therapeutics stock?

CTMX stock was purchased by a variety of institutional investors in the last quarter, including Federated Hermes Inc., Barclays PLC, Assenagon Asset Management S.A., Squarepoint Ops LLC, Charles Schwab Investment Management Inc., Virginia Retirement Systems ET AL, Taddei Ludwig & Associates Inc., and XTX Markets LLC.
View insider buying and selling activity for CytomX Therapeutics
or or view top insider-buying stocks.

How do I buy shares of CytomX Therapeutics?

Shares of CTMX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CytomX Therapeutics' stock price today?

One share of CTMX stock can currently be purchased for approximately $8.04.

How much money does CytomX Therapeutics make?

CytomX Therapeutics has a market capitalization of $371.64 million and generates $57.49 million in revenue each year. The biotechnology company earns $-102,240,000.00 in net income (profit) each year or ($2.26) on an earnings per share basis.

How many employees does CytomX Therapeutics have?

CytomX Therapeutics employs 158 workers across the globe.

What is CytomX Therapeutics' official website?

The official website for CytomX Therapeutics is www.cytomx.com.

Where are CytomX Therapeutics' headquarters?

CytomX Therapeutics is headquartered at 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080.

How can I contact CytomX Therapeutics?

CytomX Therapeutics' mailing address is 151 OYSTER POINT BLVD.SUITE 400, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-515-3185 or via email at [email protected]


This page was last updated on 2/25/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.